February 2019: Lomustine administered with temozolomide increases median survival by 16 months in patients with promoter methylation.

In Februarz 2019 German researchers from the Neurology Clinic and the Center for Integrated Oncology at the University Clinic in Bonn published  in The Lancet results of tests involving the group of 66 adult patients who were given, apart from the standard procedure (i.e. radiotherapy with temozolomide) a chemotherapeutic from the family of CCNU alkilating agents (lomustine). The mean survival was nearly doubled in comparison with the survival in the group of 63 patients who followed the standard procedure alone. However, the effect was observed only in patients with MGMT promoter methylation (unfortunately, in most patients tumors are not methylated), providing yet another argument for carrying out molecular tumor diagnosis, which can prove crucial in making decisions on preferred treatment.

Source:  here